Simon Arnett Jones - Curriculum Vitae#
EDUCATION
- 1994 PhD Biochemistry, University of Bristol
- 1990 BSc Applied Biological Sciences, Bristol Polytechnic
ACTIVE GRANTS (total income >£16M)
- 2015 - 2021 Versus Arthritis Programme Grant. £907,778. How do cytokines signalling through the transcription factors STAT1 and STAT3 determine the course of synovial inflammation? SA Jones (PI), NM Williams, GW Jones, EH Choy, AS Williams, VB O’Donnell
- 2020 - 2022 Mestag Therapeutics. Novel targeting of cytokine receptors. £347,000. SA Jones
- 2018 - 2022 GSK. £357,572. IL-27 gene therapy: SA Jones (PI), GW Jones
- 2019 - 2023 Systems Immunity/Monash University Joint PhD Scheme. £90,000. Cytokine control of disease heterogeneity in synovitis. SA Jones (PI), T Tiganis, SM Turner, NM Williams
RECOGNITION
- Grant panels
- Royal Irish Academy
- Early Entry Grant Panel (2008)
- Versus Arthritis (Arthritis Research UK)
- Research Sub-Committee (2011-16; Vice Chair 2015)
- Programme Grant Outline Panel (2015, 2016)
- USER Group (Lay panel; 2015, 2016)
- Joint Cancer Research UK Partnership Group (2018)
- Disease Sub-Committee– (Vice Chair 2017-20)
- Health & Care Research Wales
- Grants Committee (2012)
- Research for Patient & Public Benefit (Deputy Chair; 2013-18)
- Health Fellowships Committee (2014)
- Health Research Board Ireland
- Joint Medical Research Charities Panel (2016, 2018)
- Investigator Led Projects (Chair 2019)
- Trials Methodology Research Network Review Panel (Chair 2021)
- Medical Research Council UKRI
- Infection & Immunity Board (2020-24)
- COVID-19 Agile Panel (2020-21)
- Welsh Government
- Sêr Cymru II– College of Experts Independent Evaluation Panel (2015-18)
Editorial Boards
- Journal Biological Chemistry (2015-20; 2022-27)
- Frontiers in Immunology (Review Editor)
- Function
Advisory Panels
- Pharmaceutical companies
- Roche/Chugai (tocilizumab); Sanofi-Regeneron (sarilumab); Janssen, EUSA Pharma (siltuximab); Ferring (olamkicept); NovImmune SA (NI-1201; NI-101).
- Roche/Chugai (tocilizumab); Sanofi-Regeneron (sarilumab); Janssen, EUSA Pharma (siltuximab); Ferring (olamkicept); NovImmune SA (NI-1201; NI-101).
- Charities
- Versus Arthritis, Senior Stakeholder Group
- Versus Arthritis, Senior Stakeholder Group
- Government
- Welsh Higher Education Brussels Board
Society Membership
- International Cytokine & Interferon Society
- Organiser of Cytokines2021 (Chair)
- Development Committee - exploring industry links
Meetings Committee
- Learned Society of Wales
- The Royal Soc Biol
- Brit Soc Immunology
- Am Soc Mol & Cell Biol